The National Quality Forum’s Measure Applications Partnership recently released guidelines on measures for the new Merit-Based Incentive Payment System and on cross-cutting issues for all federal healthcare programs.
The National Quality Forum (NQF)’s Measure Applications Partnership (MAP) recently released guidelines on measures for the new Merit-Based Incentive Payment System (MIPS) and on cross-cutting issues for all federal healthcare programs.
The recommendations, presented by MAP, for measures in these programs, reflect how well the measures address the identified program goals, as well as NQF’s prior work in identifying families of measures. Some of the dominating issues for clinician programs identified included: the new MIPS aligning all clinician measures into a single program; further alignment of clinician measures warranted with alternative payment model and hospital/facility measures; increased public reporting of clinician measures on Physician Compare; and measuring gaps in both MIPS and Medicare Shared Savings Program.
For the purpose of the review, MAP considered 60 performance measures for use in MIPS. MIPS is a program legislated by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) in CMS. MIPS combines the Physician Quality Reporting System, the Value Modifier, and the Medicare Electronic Health Record incentive program into a single program. This single program is responsible for adjusting eligible providers’ Medicare payments based on performance.
“As the US healthcare system increasingly shifts to a performance-based payment system, MAP’s role as an impartial advisor bringing stakeholders together from across the healthcare spectrum is more important than ever,” said Helen Burstin, NQF’s chief scientific officer. “The recommendations MAP made for MIPS, MSSP, and other federal healthcare programs are advancing measurement to help make better healthcare a reality for all Americans.”
Exploring in detail, the following recommendations were proposed on cross-cutting issues to HHS:
This report highlights major changes in the types of measures submitted for consideration for use and notes that this year, for the first time, more outcome measures were submitted for consideration than process measures.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder
July 23rd 2025Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.
Read More